A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

Local Institution - 106, New York

Local Institution - 153, Marseille

Local Institution - 361, A Coruña

Local Institution - 109, Pittsburgh

Local Institution - 303, Milan

Local Institution - 111, Fairfax

Local Institution - 358, Madrid

Local Institution - 353, Madrid

Local Institution - 357, Madrid

Local Institution - 360, Majadahonda, Madrid

Local Institution - 352, Pamplona

Local Institution - 301, Aviano

Local Institution - 359, Las Palmas de Gran Canaria

Local Institution - 154, Rennes

Local Institution - 304, Verona

Local Institution - 104, Cleveland

Local Institution - 105, Canton

Local Institution - 151, Saint-Herblain

Local Institution - 362, Valencia

Local Institution - 354, Valencia

Local Institution - 102, Indianapolis

Local Institution - 306, Meldola

Local Institution - 156, Lyon

Local Institution - 110, Houston

Local Institution - 152, Villejuif

Local Institution - 107, Fort Sam Houston

Local Institution - 305, Roma

Local Institution - 451, Lodz

Local Institution - 452, Lodz

Local Institution - 454, Poznan

Local Institution - 453, Warsaw

Local Institution - 351, Badalona (Barcelona)

Local Institution - 355, Barcelona

Local Institution - 356, Barcelona

Local Institution - 254, London

Local Institution - 251, Manchester

Local Institution - 255, Sutton-Surrey